首页 | 本学科首页   官方微博 | 高级检索  
     


Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients
Affiliation:3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5T 3L9 Canada;4Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, M5T 3L9 Canada;5Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5T 3L9 Canada;6Independent researcher, Palo Alto, California 94303;**Department of Surgery, Division of Urology, Southern Alberta Institute of Urology, University of Calgary, Calgary, AB T2V 1P9, Canada;12Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5T 3L9 Canada;8Department of Surgery, Division of Urology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5T 3L9 Canada
Abstract:
><ol class=
  • Download : Download high-res image (52KB)
  • Download : Download full-size image
  • Highlights
    • •Seventy-six most promising proteins were qualified, and 19 proteins were verified by SRM in 219 seminal plasma samples of patients with prostate cancer and negative biopsies.
    • •Prostate-specific, secreted and androgen-regulated protein-glutamine gamma-glutamyltransferase 4 (TGM4) was verified by SRM assay and an in-house immunoassay.
    • •TGM4 detected prostate cancer on biopsy in seminal plasma (AUC=0.66), but not in blood serum.
    Keywords:Prostate cancer biomarkers  serum/plasma  selected reaction monitoring  absolute quantification  assay development  machine learning  protein-glutamine gamma-glutamyltransferase 4  seminal plasma  TGM4  XGBoost
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号